Final report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group).

被引：5

作者：

Sayala, Hazem A.

Moreton, Paul

Jones, Richard A.

Rawstron, Andy C.

O'Connor, Sheila J.

Evans, Paul

Anthony, Carter

Dearden, Claire

Matutes, Estella

Pettitt, Andrew R.

Kennedy, Daniel B.

Hillmen, Peter

机构：

[1] Leeds Gen Infirm, Haematol Malignacy Diag Serv, Leeds, W Yorkshire, England

[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England

[3] Canc Res Inst, London, England

[4] Leicester Royal Infirm, Leicester, Leics, England

来源：

关键词：

D O I：

10.1182/blood.V108.11.34.34

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：14A / 15A

页数：2